
Home » SANGAMO REPORTS PRECLINICAL DATA FOR ZFP THERAPEUTIC
SANGAMO REPORTS PRECLINICAL DATA FOR ZFP THERAPEUTIC
May 3, 2006
Sangamo BioSciences has announced positive preclinical animal efficacy data from its program to develop a ZFP Therapeutic for age-related "wet" macular degeneration (AMD). The study demonstrated the efficacy of zinc finger DNA-binding protein transcription factors (ZFP TF) in an animal model of macular degeneration.
A mouse model of AMD was used to test a ZFP TF designed to "turn on" the gene for PEDF, the eye's key natural regulator of normal blood vessel growth and a neuro-protective agent for the photoreceptors (cells in the eye that respond to light). Mice were treated with the ZFP TF activator of PEDF or a control administered into the vitreous space of the eye and six weeks later a laser was used to induce choroidal neovascularization (CNV), or abnormal blood vessel formation, in the eye. After a further two weeks the size of the laser-induced CNV was measured in both ZFP TF and control-treated eyes and compared. ZFP TF treatment resulted in a statistically significant reduction in CNV compared to control.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
10Mar
-
16Mar
-
18Mar
-
23Mar
-
30Mar
-
06Apr